GlassScriptPhysician profile
Nicholas William Bondio
NPI 1952961500
$2,588.46
in general payments reported to CMS, 2019-2025
16 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $228 · 2023: $896 · 2024: $861 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.93 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $458.19 | 2021-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Lilly USA, LLC | $371.71 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $197.46 | 2022-2024 | |
| Abbott Laboratories | $190.51 | 2023 | Proclaim, Freestyle Libre |
| Amgen INC. | $181.32 | 2022-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $175.20 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $144.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $80.26 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.40 | 2024-2025 | Caplyta |
| Pfizer INC. | $52.12 | 2021-2022 | |
| Boston Scientific Corporation | $28.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.55 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $19.00 | 2024 | |
| Corcept Therapeutics | $17.89 | 2025 | Korlym |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Bondio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.